HIV treatment breakthrough creates antibody that attacks 99 per cent of virus' strains
Pathogen kills more than one million people each year around the world
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.An antibody that attacks 99 per cent of HIV strains has been developed by scientists for the first time.
The “exciting breakthrough” could eventually lead to treatment or even prevent transmission of the virus, with trials on humans due to get underway in 2018.
Experiments on 24 monkeys injected with HIV showed none developed the virus after first being given the new type of antibody, which attacks three critical parts of the disease.
The human immune system struggles to deal with HIV due to its ability to mutate and change appearance. Our bodies eventually become overwhelmed by the number of different strains of the virus.
But around one per cent of patients have the ability to develop “broadly neutralising antibodies”. These bind to structures on the surface of the pathogens known as “spikes”.
Spikes barely change and are identical among different strains, making it possible for these special antibodies to attack different mutations of the virus.
Now scientists have managed to combine three of these flexible antibodies into a powerful “tri-specific antibody”.
Dr Gary Nabel, chief scientific officer at pharmaceutical company Sanofi and one of the report authors, told the BBC the results were “impressive”.
“They are more potent and have greater breadth than any single naturally occurring antibody that's been discovered," he said.
"We're getting 99 per cent coverage, and getting coverage at very low concentrations of the antibody.”
An estimated 36.7 million people worldwide were living with HIV or AIDS at the end of 2015, with the majority in sub-Saharan Africa. Of these, only 60 per cent of people are aware they have it.
In 2015 alone 1.1 million people died from the disease.
The study was published in the journal Science, and is a collaboration between the US National Institutes of Health and Sanofi.
The research included contributions from scientists at Harvard Medical School, The Scripps Research Institute and the Massachusetts Institute of Technology.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments